Adoptive T-cell transfer in melanoma. (January 2013)

• Record Type: Journal Article
• Authors: Itzhaki, Orit; Levy, Daphna; Zikich, Dragoslav; Treves, Avraham J; Markel, Gal; Schachter, Jacob; Besser, Michal J
• Is Part Of: Immunotherapy. Volume 5:Number 1(2013:Jan.)
• Page Start: 79
• Page End: 90
• Publication Date: 2013-01
• Subjects: ACT -- adoptive cell transfer -- CAR -- chimeric antigen receptor -- genetically modified T cell -- melanoma -- TIL -- tumor-infiltrating lymphocyte; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.12.143
• Languages: English
• ISSNs: 1750-743X

Abstract

Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymphocytes demonstrates objective clinical responses in 50–72% of the patients, including 10–40% complete responses and was shown to produce durable disease control with long progression-free survival. Tumor-infiltrating T-lymphocyte ACT might even have curative potential as the vast majority of the complete responders are without any evidence of disease many years after treatment. Other adoptive transfer studies employ the genetic modification of T lymphocytes with genes encoding tumor-specific T cell receptors or antibody-based chimeric antigen receptors. These approaches opened numerous possibilities to treat cancers other than melanoma. In this article we will summarize the ACT strategies in melanoma, the new developments in this field and combinations with other therapies.